Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Hisao ImaiHiroyuki MinemuraTakayuki KishikawaYutaka YamadaKensuke SuzukiYukihiro UmedaSatoshi WasamotoNorimitsu KasaharaShinichi IshiharaOu YamaguchiIchiro NaruseJunji UchinoKeita MoriKenya KanazawaYoko ShibataTakashi KasaiTakayuki KaburagiKyoichi KairaKoichi MinatoPublished in: Thoracic cancer (2020)
S-1 monotherapy is effective and feasible as a subsequent-line treatment in elderly patients who were previously treated for NSCLC, and it produces results. S-1 monotherapy could be one of the treatment choices for elderly patients with previously treated NSCLC.